Insmed to Host Fourth Quarter and Year-end 2016 Financial Results Conference Call on Thursday, February 23, 2017
February 16 2017 - 7:00AM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
today announced that it will release its fourth quarter and
year-end financial results on Thursday, February 23, 2017.
Will Lewis, president and chief executive officer, and Andy
Drechsler, chief financial officer, will host a conference call for
investors beginning at 8:30 a.m. ET on Thursday, February 23, 2017
to discuss the financial results and provide a business update.
Shareholders and other interested parties may participate in the
conference call by dialing (844) 707-0669 (domestic) or (703)
639-1223 (international) and referencing conference ID number
62287854. The call will also be webcast live on the internet on the
company's website at www.insmed.com.
A replay of the conference call will be accessible approximately
two hours after its completion through March 9, 2017 by dialing
(855) 859-2056 (domestic) or (404) 537-3406 (international) and
referencing conference ID number 62287854. A webcast of the call
will also be archived for 90 days under the Investor Relations
section of the company's website at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company
focused on the unmet needs of patients with rare diseases. The
company is advancing a global phase 3 clinical study of ARIKAYCE
(liposomal amikacin for inhalation) in nontuberculous mycobacteria
(NTM) lung disease, a rare and often chronic infection that is
capable of causing irreversible lung damage and can be fatal. There
are currently no approved products indicated for the treatment of
NTM lung disease in the United States or European
Union (EU). Insmed's earlier-stage clinical pipeline includes
INS1007, a novel oral reversible inhibitor of DPP1 with therapeutic
potential in non-CF bronchiectasis, and INS1009, an
inhaled nanoparticle formulation of a treprostinil prodrug
that may offer a differentiated product profile for rare pulmonary
disorders. For more information, visit www.insmed.com.
"Insmed" and "ARIKAYCE" are the company's trademarks. All other
trademarks, trade names or service marks appearing in this press
release are the property of their respective owners.
Investor Contact:
Laura Perry
Argot Partners
646.439.0410
laura@argotpartners.com
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Apr 2023 to Apr 2024